Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Gold Price Monitor -- Ignore unavailable to you. Want to Upgrade?

To: E. Charters who wrote (93297)	2/4/2003 11:12:09 PM
From: long-gone	Respond to of 116790

Just as the Spanish Flu, WWI, & the electrification / Radio / industrial revolution of the 20's brought about deflation & the resulting "Great Depression" History has repeated. AIDS reduced the rate of world population growth & recent productivity gains made matters worse. Here it is brothers & sisters, that which will yield the world human population growth spurt needed to drive the next great round of inflation. Testing a New HIV Vaccine Wed Jan 29,11:56 PM ET Add Health - HealthScoutNews to My Yahoo! WEDNESDAY, Jan. 29 (HealthScoutNews) -- A clinical trial of a new AIDS (news - web sites) vaccine begins this month at three locations in the United States. The Phase I clinical trial will include 30 people at the University of Alabama at Birmingham, the University of Washington in Seattle, and the San Francisco Department of Public Health (news - web sites). This vaccine strategy includes two different components -- two inoculations of a DNA vaccine that primes the immune system to recognize HIV (news - web sites), followed by a booster vaccine based on a recombinant poxvirus. Neither of these components incorporates the actual HIV virus (news - web sites). Instead, the vaccine produces the three major proteins expressed by HIV. That primes the body's immune system to respond to the distinguishing features of HIV so it is ready to battle the virus if it enters the body, the researchers say. The trial will last one year. It will focus on assessing the safety of the primer DNA vaccine among people who are HIV-negative. They'll be randomly assigned to receive either a high-dose vaccine, low-dose vaccine or a placebo. A separate trial will examine the safety of the booster vaccine, and a third trial will test the safety of the combined regimen. The vaccine was developed at the Yerkes Primate Research Center of Emory University, the Emory Vaccine Center, and the Laboratory of Viral Diseases at the U.S. National Institute of Allergy and Infectious Diseases (news - web sites). story.news.yahoo.com